Clinical trial · Interventional
Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance
Assessment of the Biological Effect of Autophagic Inhibition With Hydroxychloroquine in Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): slow accrual
Summary
Brief summary (as posted)
This phase 0 trial studies hydroxychloroquine in blocking autophagy in patients with prostate cancer who are undergoing surgery or active surveillance. Autophagy is a process in which cells break down some parts of themselves to stay alive during times of stress, such as starvation. This may allow cancer cells to survive damage from chemotherapy. Hydroxychloroquine may block this process from happening.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Carcinoma | Prostate Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hydroxychloroquine | Drug | Hydroxychloroquine | ALIAS |
| Laboratory Biomarker Analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Group I, Arm I (lower dose hydroxychloroquine)
- description
- Patients receive hydroxychloroquine PO QD for 14 days and then undergo prostatectomy.
- interventionNames
- Drug: Hydroxychloroquine
- Other: Laboratory Biomarker Analysis
- type
- EXPERIMENTAL
- label
- Group I, Arm II (higher dose hydroxychloroquine)
- description
- Patients receive hydroxychloroquine PO TID for 14 days and then undergo prostatectomy.
- interventionNames
- Drug: Hydroxychloroquine
- Other: Laboratory Biomarker Analysis
- type
- EXPERIMENTAL
- label
- Group II (mid-dose hydroxychloroquine)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Signed written informed consent * Have abnormal digital rectal examination, or abnormal prostate specific antigen (\> 4.0 ng/ml), or obstructing prostate, or biopsy proven prostate cancer * Scheduled for prostate surgery, i.e. transurethral resection of the prostate (TURP) or prostatectomy * Planned to be treated by active surveillance Exclusion Criteria: * Patients on treatment for rheumatoid arthritis or systemic lupus erythematosus * Patients with psoriasis * Patients receiving any disease-modifying anti-rheumatic drug (DMARD) * Active clinically significant infection requiring antibiotics * Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency * Patients taking other commercially available medications which may theoretically either stimulate or inhibit autophagy, which are calcitriol and chloroquine * Patients taking medications which may lead to interactions with hydroxychloroquine, including penicillamine, telbivudine, botulinum toxin, digoxin, and propafenone * Patients must not have prior visual field changes from prior 4-aminoquinoline compound use * Must not be taking hydroxychloroquine for treatment or prophylaxis of malaria * History of hypersensitivity to 4-aminoquinoline compound
References
Publications (0)
Data not yet available